Literature DB >> 24104065

Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.

Robert W Motl1, Diego Cadavid, Brian M Sandroff, Lara A Pilutti, John H Pula, Ralph H B Benedict.   

Abstract

BACKGROUND: The Multiple Sclerosis Walking Scale-12 (MSWS-12) has been a commonly used patient reported outcome for measuring walking impairment in research involving multiple sclerosis (MS).
OBJECTIVE: We examined the possibility that cognitive processing speed (CPS) influences the association between MSWS-12 scores and other measures of ambulation (i.e., construct validity).
METHODS: 96 MS patients completed the MSWS-12, underwent a neurological examination for generating an Expanded Disability Status Scale (EDSS) score, and completed the Symbol Digit Modalities Test (SDMT), Timed 25-Foot Walk (T25FW), 4 trials on the GAITRite™ for generating the functional ambulatory profile (FAP) score, and Six-minute Walk (6MW).
RESULTS: The SDMT was significantly correlated with MSWS-12 scores (r=-.428) and T25FW (r=-.459), 6MW (r=.512), FAP (r=.275), and EDSS (r=-.404) scores. There were statistically significant correlations between MSWS-12 and T25FW (r=.568), 6MW (r=-.680), FAP (r=-.595), and EDSS (r=.737) scores. Lastly, four separate hierarchical linear regression analyses indicated that, after controlling for age, gender, disease duration, and clinical course, T25FW, 6MW, FAP, and EDSS scores individually were significant correlates of MSWS-12 scores, and the associations (i.e., standardized beta-coefficients) were still statistically significant with minimal attenuation when controlling for SDMT scores.
CONCLUSION: There was minimal evidence that CPS influenced the construct validity of MSWS-12 scores.
© 2013.

Entities:  

Keywords:  Cognition; Gait; Measurement; Multiple sclerosis; Validity; Walking

Mesh:

Year:  2013        PMID: 24104065     DOI: 10.1016/j.jns.2013.09.024

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Cognitive Processing Speed Impairment Does Not Influence the Construct Validity of Six-Spot Step Test Performance in People With Multiple Sclerosis.

Authors:  Brian M Sandroff; Stephanie L Silveira; Jessica F Baird; Trinh Huynh; Robert W Motl
Journal:  Phys Ther       Date:  2021-02-04

2.  The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.

Authors:  Damiano Mistri; Laura Cacciaguerra; Loredana Storelli; Alessandro Meani; Claudio Cordani; Maria A Rocca; Massimo Filippi
Journal:  J Neurol       Date:  2022-03-12       Impact factor: 6.682

3.  Longitudinal changes in self-reported walking ability in multiple sclerosis.

Authors:  Robert W Motl; Norman Putzki; Lara A Pilutti; Diego Cadavid
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

4.  Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Authors:  Robert W Motl; Jeffrey A Cohen; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

5.  Cognitive Function and Whole-Brain MRI Metrics Are Not Associated with Mobility in Older Adults with Multiple Sclerosis.

Authors:  Jessica F Baird; Robert W Motl
Journal:  Int J Environ Res Public Health       Date:  2021-04-16       Impact factor: 3.390

6.  Cognitive-motor telerehabilitation in multiple sclerosis (CoMoTeMS): study protocol for a randomised controlled trial.

Authors:  Delphine Van Laethem; Frederik Van de Steen; Daphne Kos; Maarten Naeyaert; Peter Van Schuerbeek; Miguel D'Haeseleer; Marie B D'Hooghe; Jeroen Van Schependom; Guy Nagels
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

7.  A quantitative method for measuring the relationship between an objective endpoint and patient reported outcome measures.

Authors:  Chul Ahn; Xin Fang; Phyllis Silverman; Zhiwei Zhang
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.